IRIS UniCatt

Rossi, Elena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.597
EU - Europa 2.395
AS - Asia 1.363
SA - Sud America 379
AF - Africa 56
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.804
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.546
DE - Germania 690
SG - Singapore 573
SE - Svezia 439
CN - Cina 399
IT - Italia 394
BR - Brasile 337
FR - Francia 168
UA - Ucraina 142
IE - Irlanda 124
PL - Polonia 107
GB - Regno Unito 105
IN - India 83
ID - Indonesia 79
RU - Federazione Russa 58
FI - Finlandia 54
VN - Vietnam 49
AT - Austria 30
IQ - Iraq 28
CA - Canada 27
KR - Corea 20
AR - Argentina 16
BD - Bangladesh 16
HK - Hong Kong 16
BE - Belgio 15
CI - Costa d'Avorio 15
MX - Messico 15
TR - Turchia 15
NL - Olanda 13
SA - Arabia Saudita 12
ZA - Sudafrica 12
ES - Italia 11
IR - Iran 10
AU - Australia 9
PK - Pakistan 9
JP - Giappone 8
LT - Lituania 8
UZ - Uzbekistan 7
CH - Svizzera 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
DZ - Algeria 5
PE - Perù 5
UY - Uruguay 5
CL - Cile 4
EC - Ecuador 4
LV - Lettonia 4
MY - Malesia 4
RO - Romania 4
TH - Thailandia 4
TN - Tunisia 4
VE - Venezuela 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CZ - Repubblica Ceca 3
EE - Estonia 3
EG - Egitto 3
JM - Giamaica 3
KE - Kenya 3
KZ - Kazakistan 3
DK - Danimarca 2
GA - Gabon 2
HU - Ungheria 2
IL - Israele 2
JO - Giordania 2
KG - Kirghizistan 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
PY - Paraguay 2
SN - Senegal 2
TW - Taiwan 2
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
KH - Cambogia 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
Totale 6.804
Salva come PNG Salva come JPEG
Città #
Chandler 485
Singapore 238
Ashburn 237
Dublin 119
Wilmington 94
San Mateo 86
Jacksonville 85
Rome 82
Fairfield 80
Warsaw 78
Jakarta 76
Munich 75
Beijing 74
Milan 67
Ann Arbor 66
New York 62
Cattolica 61
Dearborn 61
Nanjing 61
Boston 58
Houston 58
Woodbridge 56
Los Angeles 46
Seattle 40
Marseille 39
Moscow 39
Princeton 38
Hefei 35
Hyderabad 33
São Paulo 33
Redwood City 32
Chicago 29
Frankfurt am Main 26
Lawrence 26
Nürnberg 25
Detroit 23
Kraków 23
Redmond 23
Nanchang 22
Cambridge 20
Bologna 18
Hangzhou 18
Nuremberg 18
Hanoi 17
Hebei 17
Seoul 17
Hong Kong 16
Abidjan 15
Boardman 15
Brussels 15
London 15
Washington 15
Helsinki 14
Leawood 14
Norwalk 14
Vienna 14
Toronto 13
Belo Horizonte 11
Paris 11
Brooklyn 10
Changsha 10
Düsseldorf 10
Florence 10
Ho Chi Minh City 10
The Dalles 10
Tianjin 10
Bremen 9
Mountain View 9
San Diego 9
Bexley 8
Pune 8
Rio de Janeiro 8
Turku 8
Baghdad 7
Buenos Aires 7
Erbil 7
Guangzhou 7
Kunming 7
Portsmouth 7
Santa Clara 7
Tashkent 7
University Park 7
Busto Arsizio 6
Campinas 6
Cape Town 6
Charlotte 6
Dhaka 6
Lancaster 6
Shenyang 6
Wroclaw 6
Atlanta 5
Baku 5
Izmir 5
Jiaxing 5
Madrid 5
Mexico City 5
Montreal 5
Ottawa 5
Perugia 5
Porto Alegre 5
Totale 3.488
Salva come PNG Salva come JPEG
Nome #
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 290
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. 281
Haemostatic alterations induced by treatment with asparaginases and clinical consequences 212
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 192
Risk factor and etiology analysis of ischemic stroke in young adult patients 159
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 152
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 148
Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. 145
Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience. 142
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 139
Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms 131
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments 129
Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia 125
Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms 118
Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms 117
Venous thromboembolism in multiple myeloma 114
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 114
JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis 112
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 109
Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation 102
The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia 101
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 101
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 99
Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities 98
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 97
Inherited thrombophilia: treatment during pregnancy. 94
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 93
Assessment of congenital neutropenia in children: common clinical sceneries and clues for management 91
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 90
Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation 88
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists 88
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 87
In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband 85
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 83
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 82
Isolated light chain deposition disease neuropathy in a patient with multiple myeloma 78
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 78
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 77
Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups 76
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 73
Structural analysis of protein Z gene variants in patients with foetal losses 70
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 70
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years 70
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 69
Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia 68
Cerebral sinus-venous thrombosis 66
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 64
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 63
Venous thromboembolism in patients with liver diseases 63
Venous thromboembolism in patients with liver diseases 63
Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis? 61
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 61
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study 61
Contractile reserve of dysfunctional myocardium after revascularization: A dobutamine stress echocardiography study 61
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 60
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 59
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 59
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 58
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 58
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 57
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 56
Reassessment of contractile reserve after revascularization of akinetic myocardium 56
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 54
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms 53
Second cancers in MPN: Survival analysis from an international study 52
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus 47
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 43
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 42
G20210A protrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 41
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 40
Methylation Analysis of Urinary Sample in Non-Muscle-Invasive Bladder Carcinoma: Frequency and Management of Invalid Result 40
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 40
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 38
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial 37
Coagulopathy in CAR-T: Critical concern or mere blip? 36
Risk factor and etiology analysis of ischemic stroke in young adult patients 34
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 34
Glycoprotein IA C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up. 34
Left atrial myxoma supplied from the right coronary artery 31
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 27
ROLE OF 18 F-FDG PET/CT IN THE ASSESSMENT OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA 25
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 24
Totale 6.935
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.839
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.839
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021452 0 43 20 56 49 37 53 22 56 26 76 14
2021/2022668 46 35 16 40 32 13 20 80 45 45 121 175
2022/20231.356 203 197 115 199 77 159 79 84 154 25 35 29
2023/2024742 28 177 30 52 34 127 37 40 14 31 80 92
2024/20251.552 26 67 91 62 121 37 59 71 254 165 325 274
2025/2026651 601 50 0 0 0 0 0 0 0 0 0 0
Totale 6.935